Key takeaways for New Jersey
- • FDA labels require BMI 30+ or 27+ with comorbidity for approved weight-loss GLP-1s.
- • Mean weight loss: roughly 15% with semaglutide, roughly 21% with tirzepatide at one year.
- • Weight regain is common after stopping — most clinicians frame this as chronic therapy.
- • NJ FamilyCare coverage rules apply for Obesity / Chronic Weight Management patients in New Jersey — see Medicaid section below.
- • 16 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Obesity / Chronic Weight Management
Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved specifically for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. Evidence grade: A. STEP and SURMOUNT trial programs established mean total body weight loss of approximately 15% with semaglutide 2.4 mg and approximately 21% with tirzepatide 15 mg at 72 weeks. Saxenda (liraglutide 3.0 mg) is also approved but less effective. Weight regain is common after discontinuation, so most experts treat obesity as chronic and indefinite, similar to hypertension.
New Jersey-specific context
New Jersey has telehealth access concentrated in Newark, Jersey City, Paterson metros, with additional reach to Elizabeth and Edison. RWJBarnabas Health, Hackensack Meridian Health, Atlantic Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.nj.gov/health.
New Jerseytelehealth & pricing rules
- • New Jersey requires a live video consultation before a GLP-1 prescription.
- • New Jersey allows new-patient telehealth prescribing without a prior in-person visit.